Dr. Reddy’s Laboratories (RDY) Comments on Recent Media Reports
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Join SI Premium – FREE
Dr. Reddy’s Laboratories (NYSE: RDY) wishes to clarify that the media reports highlighting its troubles with the US health authorities related to certain promotional material for Fondaparinux Sodium are misleading .
Dr. Reddy’s had received a communication from the Division of Professional Promotion (DPP), US FDA directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012 that the matters are now considered closed.
Dr. Reddy’s had received a communication from the Division of Professional Promotion (DPP), US FDA directing for changes related to certain promotional material for Fondaparinux Sodium for Injection. The company has already addressed all matters raised by the DPP, US FDA in the letter issued on January 10, 2012. The DPP informed Dr. Reddy's Laboratories on January 24, 2012 that the matters are now considered closed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Cytek faces $56M damages award in Beckman Coulter patent case
- Boeing names Ryan Shedd as new SVP and controller
Create E-mail Alert Related Categories
Corporate News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
